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Most DNA polymerases are multifunctional proteins that possess both polymerizing and exonucleolytic
activities. For Escherichia coli DNA polymerase I and its relatives, polymerase and exonuclease activities reside
on distinct, separable domains of the same polypeptide. The catalytic subunits of the a-like DNA polymerase
family share regions of sequence homology with the 3'-5' exonuclease active site of DNA polymerase I; in
certain a-like DNA polymerases, these regions of homology have been shown to be important for exonuclease
activity. This finding has led to the hypothesis that a-like DNA polymerases also contain a distinct 3'-5'
exonuclease domain. We have introduced conservative substitutions into a 3'-5' exonuclease active site
homology in the gene encoding herpes simplex virus DNA polymerase, an a-like polymerase. Two mutants
were severely impaired for viral DNA replication and polymerase activity. The mutants were not detectably
affected in the ability of the polymerase to interact with its accessory protein, UL42, or to colocalize in infected
cell nuclei with the major viral DNA-binding protein, ICP8, suggesting that the mutation did not exert global
effects on protein folding. The results raise the possibility that there is a fundamental difference between a-like
DNA polymerases and E. coli DNA polymerase I, with less distinction between 3'-5' exonuclease and
polymerase functions in a-like DNA polymerases.
DNA polymerases are central to the replication of genetic
material. Much of our information regarding DNA polymer-
ases has come from detailed structural, enzymological, and
genetic studies of Escherichia coli DNA polymerase I (Pol I)
and its relative, T7 DNA polymerase (33, 61). However,
most eukaryotic cellular and viral replicative DNA poly-
merases and certain bacterial and bacteriophage DNA poly-
merases are members of the (x-like polymerase family and
share only very limited sequence similarity with Pol I (1, 39,
45, 60, 68). A fundamental question is: Do these enzymes
carry out their functions similarly to or differently from Pol
I?
DNA polymerases usually contain both polymerase and
exonucleolytic activities either on a single polypeptide or as
separate subunits. The 3'-5' exonuclease activities associ-
ated with polymerases frequently perform proofreading
functions, thereby reducing replication errors and mutation
rates. A key feature of Pol I is that its polymerase and 3'-5'
exonuclease activities reside on a single polypeptide (37) as
separate domains with the active sites about 3 nm apart (47).
This physical separation translates into functional indepen-
dence, as revealed by analysis of mutations, including fairly
gross deletions, of Pol I and T7 DNA polymerase that
inactivate 3'-5' exonuclease activity without major deleteri-
ous effects on polymerase activity and processivity (11, 12,
19, 61).
Interestingly, a-like DNA polymerases share sequence
similarities with active sites in the 3'-5' exonuclease domain
of Pol I (2, 39, 45, 60). Bernad et al. (2) have termed these
segments Exo I, Exo II, and Exo III (Fig. 1). Exo I and Exo
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II lie within region IV of sequence homology among a-like
DNA polymerases (75), while Exo III lies roughly 50 to 150
amino acids downstream in any of the polymerases. That
these segments are important for 3'-5' exonuclease activity
has been confirmed by mutational analyses of the a-like
polymerases of bacteriophages +29 and T4. Several bacte-
riophage T4 mutations resulting in either altered mutation
rates, reduced 3'-5' exonuclease activity, or both reside in
these segments or elsewhere in a region extending from 90
amino acids upstream of Exo I to 20 amino acids down-
stream of Exo III (52-55). Bernad et al. (2) have shown that
mutagenesis of specific residues within Exo I and Exo II of
+29 DNA polymerase results in an enzyme that retains
polymerase activity but is deficient in 3'-5' exonuclease
activity. These results have led to the hypothesis that a-like
DNA polymerases, like Pol I, are modular in organization
with relative functional and structural independence of poly-
merase and exonuclease domains (2, 52, 53).
Herpes simplex virus (HSV) encodes a DNA polymerase
(HSV Pol) that is a member of the a-like polymerase family
and contains an intrinsic 3'-5' exonuclease activity (41).
Because of the ease with which polymerase function can be
studied by pharmacological, genetic, and molecular tech-
niques in the authentic context of the virus-infected cell,
HSV Pol has been valuable for determining the functional
relevance of regions of sequence similarity shared among
a-polymerases. In particular, regions I, II, III, V, and A
(Fig. 1) are considered to be involved in substrate binding
and polymerizing activity, as concluded from the clustering
of mutations in these regions that result in alterations in the
sensitivity of HSV to various antiviral drugs and aphidicolin,
which mimic and/or compete with deoxynucleoside triphos-
phate (dNTP) and pyrophosphate substrates (22, 28, 31, 35,
38, 42, 67).
To understand the functional importance of one of the
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FIG. 1. The Exo II region of homology shared among diverse DNA polymerases. (A) Schematic of the HSV Pol polypeptide. The locations
of regions I to VI of sequence similarity shared among a-like polymerases compiled by Wang et al. (68), region A (22), and the UL42 binding
domain (14) are shown as open boxes; the Exo I, II, and III segments of Bemad et al. (2) are depicted as dark boxes. The numbers above
the line refer to amino acid residues; the vertical lines below refer to the locations of mutations that confer resistance or hypersensitivity to
polymerase substrate analogs. (B) Amino acid sequences of several DNA polymerases in the Exo II segment (2). Numbers refer to amino acid
residues. Conserved residues are shaded. Polymerase sequences: E. coli Pol (32), T7 (15), T5 (39), 429 (78), T4 (60), adenovirus (AdV) (25),
human DNA polymerase a (HUM) (75); yeast DNA polymerase (CDC2) (4); vaccinia virus (VV) (36, 65); Epstein-Barr virus (EBV) (1), and
HSV (23). (C) Mutations described in this report.
reported homologies with the 3'-5' exonuclease active site of
Pol I, we have engineered mutations in this region, recom-
bined them into HSV, and examined their effects on poly-
merase functions in vitro and in vivo. Our results lead us to
consider the possibility that a-like DNA polymerases differ
fundamentally from E. coli Pol I in the relationship between
polymerase and 3'-5' exonuclease -activities.
MATERIALS AND METHODS
Plasmids and oligonucleotides. pDP1 (42) consists of HSV
pol sequences extending from about 150 bp upstream of the
major open reading frame to about 150 bp downstream,
cloned into pUC19. MD18.1 contains the insert of pDP1
cloned into M13mpl8 (77) which had been digested with
HindIII and Salll. All oligonucleotides were purchased from
Genetic Designs, Inc., Houston, Tex.
Cells and viruses. African green monkey kidney (lines
Vero and CV-1) and human osteosarcoma (line 143) cells
were propagated and maintained as described previously
(71). DP6 cells, which contain the HSV pol gene and permit
the growth of otherwise nonviable HSV pol mutants, were
propagated and maintained similarly except that they were
passaged in G418 (500 jig/ml; GIBCO Laboratories) once
each month. HSV wild-type strain KOS, recombinant virus
HP66, and mutants E460D, V462A, and G464V (this report)
were grown and titered as described previously (9). The
derivation of the DP6 cell line and the use of recombinant
virus HP66 for identifying pol recombinants are described in
detail elsewhere (40, 42).
Mutagenesis. Oligonucleotide-directed site-specific muta-
genesis was performed on MD18.1 by the method of Taylor
et al. (63), which relies on the resistance of phosphorothio-
ate-modified DNA to digestion by some restriction enzymes.
All reagents necessary for this procedure were purchased as
a kit from Amersham. The procedure was adapted by using
degenerate oligonucleotides contaminated at each residue
with 1.2% of each of the other three deoxyribonucleotides
during synthesis. The wild-type sequence of the oligonucle-
otide used in mutagenesis is CCCGAGTTCGTGACTGGG
TACAAC. The underlined sequence refers to an NciI re-
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striction site that was altered as an internal control without
altering the sequence of the encoded protein.
Marker rescue. Marker rescue experiments were per-
formed essentially as described previously (7), with the
following exceptions. DP6 cells were used in all cases. A
5-fold molar excess of bacteriophage RF or a fragment
derived from pDP1 or a 25-fold molar excess of single-
stranded bacteriophage DNA was cotransfected with 1 ,ug of
infectious DNA. After all cells were infected, virus was
harvested and the progeny virus was assayed for titer on
Vero cells and DP6 cells (9).
Southern hybridization analysis. To screen virus for proper
recombination of mutant sequences, the method of Southern
(59) was used. Approximately 18 h after infection of DP6
cells at a multiplicity of infection of 3, DNA was harvested
by a modification of the Hirt method (30). Briefly, 6 x 106
infected cells were lysed directly in 1 ml of 0.6% sodium
dodecyl sulfate (SDS), and sodium chloride was added to 1
M. After 18 h at 4°C, chromatin was pelleted by centrifuga-
tion in a microfuge for 15 min. The supernatant containing
HSV DNA was then extracted with phenol and chloroform,
followed by ethanol precipitation and RNase digestion by
standard methods.
DNA was digested with either Ncil (New England Bio-
Labs, Beverly, Mass.) or EcoRI (American Allied, Aurora,
Colo.) according to the manufacturer's directions and sub-
jected to agarose gel electrophoresis. The resulting digests
were transferred to GeneScreen Plus (New England Nu-
clear, Boston, Mass.) by capillary blotting, cross-linked with
UV radiation (8), and hybridized according to the directions
supplied by New England Nuclear with a 32P-labelled oligo-
nucleotide probe. To detect EcoRI fragments containing the
3' end of the pol gene, an oligonucleotide with the sequence
CGCGGGTCTGGGCCACG was used. To detect Ncil frag-
ments containing region IV, an oligonucleotide with the
sequence CGACCTCCCCGAATCCC was used.
DNA sequencing. DNA sequencing was by the dideoxy
synthesis method (57) as previously described (22, 23), using
synthetic oligonucleotide primers designed to hybridize with
the HSV pol gene.
Dot blot hybridization analysis. A modification of the
method of Gadler et al. (20) was used to assay replication of
HSV DNA in cell culture. DP6 or Vero cells growing in
96-well trays (Falcon) were infected at a multiplicity of
infection of 3 and incubated for 18 h at 37°C. The medium
was then aspirated, each well was rinsed twice with 200 ,ul of
trypsin diluent, and the cells were lysed with 200 [lI of 0.5 M
NaOH. The lysed cells were then neutralized with 20 [LI of 10
M ammonium acetate and spotted onto GeneScreen II Plus
which was prewet with 1 M ammonium acetate-20 mM
NaOH in a manifold apparatus (Schleicher & Schuell,
Keene, N.H.). The filters were washed with 1 M ammonium
acetate-20 mM NaOH (100 ,ul per well) and removed from
the manifold. The filters were then soaked in 4x SSPE for 2
min, UV cross-linked for 5 min (8), and hybridized to a 32p_
labelled oligonucleotide, CGACCTCCCCGAATCCC, com-
plementary to the HSV pol gene, according to the directions
supplied by New England Nuclear.
DNA polymerase assays. 143 cells in 100-mm dishes were
mock infected or infected with wild-type or mutant HSV at
a multiplicity of infection of 10 and incubated at 37°C. Eight
hours after infection, the medium was removed and the cells
were washed twice with phosphate-buffered saline (PBS),
scraped into PBS, and sedimented by centrifugation at 1,000
x g for 10 min. The cell pellet was resuspended in 200 ,ul of
20 mM Tris-HCl (pH 7.5)-i mM EDTA-100 mM NaCl-10
mM P-mercaptoethanol. Cells were disrupted by sonication
in a cup horn sonicator, and cell debris was removed by
centrifugation in a microfuge at 13,000 x g for 10 min. DNA
polymerase was assayed under conditions that favor detec-
tion of HSV Pol versus cellular polymerases. The reaction
mix contained, in a final volume of 50 ,ul, 20 mM Tris-HCl
(pH 7.5); 100 mM (NH4)2SO4; 0.1 mM EDTA; 0.5 mM
dithiothreitol; 10% glycerol; 500 ,ug of activated salmon
sperm DNA per ml, prepared as described previously (69);
60 puM each dATP, dGTP, and dTTP; 5 p.M [32P]dCTP (1,600
cpm/pmol); and S [l of cell extract (0.75 ,ug of protein, as
determined by using a Bio-Rad assay kit and bovine serum
albumin as a standard). Reactions were started by addition
of cell extract and were incubated at 37°C for 20 min.
Reactions were terminated by addition of trichloroacetic
acid to a final concentration of 10%. The resulting precipitate
was collected on a Whatman GF/C filter, and the acid-
precipitable radioactivity was estimated in a liquid scintilla-
tion counter. To ensure that results were obtained in the
linear range of the assay, a standard curve with dilutions of
wild-type virus-infected extract in mock extract was per-
formed in parallel.
Western immunoblot analysis. A 30-,ul sample of each cell
extract prepared for DNA polymerase assays was incubated
under DNA polymerase assay conditions as described
above. Following incubation, samples were boiled in SDS
sample buffer, electrophoresed through SDS-polyacrylamide
gels, and then transferred to nitrocellulose as described by
Towbin et al. (64). The nitrocellulose was then reacted with
a 1:1,000 dilution of a polyclonal rabbit antiserum (PP5)
directed against a ,-galactosidase-polymerase fusion protein
expressed in bacteria (76). Bound antibodies were detected
with a 125I-labeled goat anti-rabbit conjugate (ICN) and
visualized by autoradiography. Filters were then stripped of
bound antibodies by incubation in 0.1 M glycine-HCl (pH
2.5) twice for 10 min each time at room temperature and
reprobed with polyclonal rabbit antiserum 3-83, directed
against ICP8 (34), followed by detection with labeled goat
anti-rabbit conjugate as described above. The autoradio-
graphic signals were quantified by densitometric scanning.
To ensure that signals were within the linear range of the
assay, a dilution series of KOS-infected cell extract diluted
with mock-infected cell extract was simultaneously applied
to the gel.
Assay of HSV Pol-UL42 complex formation. Assays of
complex formation between HSV Pol and UL42 were per-
formed as described by Digard and Coen (14) except that the
anti-UL42 antiserum used was 13809, a polyclonal rabbit
serum prepared against purified UL42 (43).
Assay of localization of HSV Pol and ICP8 in infected cells.
Double-label immunofluorescence assays of the intracellular
distribution of HSV Pol and ICP8 in infected CV-1 cells were
performed as described by Bush et al. (5), with the following
modifications. Infected cells were fixed for 10 min in 2%
formaldehyde and then for 2 min in ice-cold acetone. They
were then reacted for 30 min at room temperature with a
mixture of a 1:10 dilution of rabbit anti-HSV Pol antiserum
and PP5 (76) and with a 1:30 dilution of mouse monoclonal
anti-ICP8 antibody 39S (58), for 30 min with a mixture of
goat anti-mouse immunoglobulin conjugated with rhodamine
and goat anti-rabbit immunoglobulin conjugated with biotin,
and then for 30 min with fluorescein isothiocyanate-avidin
(Cappel/Organon Teknika).
MOL. CELL. BIOL.
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RESULTS
Mutagenesis of Exo II sequences. Mixed oligonucleotides
were designed to target an eight-amino-acid stretch contain-
ing both highly conserved and nonconserved amino acids
within the Exo II segment defined by Bernad et al. (2), which
lies within region IV of homology among a-like DNA poly-
merases (Fig. 1). As an internal control, the oligonucleotides
also contained a mutation that destroyed an Ncil recognition
site without changing the amino acid sequence. These oligo-
nucleotides were used to mutagenize single-stranded DNA
from the HSV pol construct MD18.1. Mutagenized DNA
was transfected into E. coli, and plaques were picked and
screened for alterations within the targeted segment by DNA
sequencing. We describe results with three engineered mu-
tations here: E460D, V462A, and G464V (the first letter
denotes the wild-type amino acid, the number denotes the
residue position, and the last letter denotes the mutant amino
acid). The glutamic acid at residue 460 is relatively noncon-
served, the valine at residue 462 is at a position that is
usually nonpolar, and the glycine at residue 464 is highly
conserved among the oa-polymerases and is also found at the
corresponding position in Pol I. These residues lie just
upstream of a conserved aspartic acid residue (position 471
in HSV) (Fig. 1), which, when mutated in E. coli Pol I and
429, greatly decreased exonuclease activity without appar-
ent effects on polymerase activity (2, 12, 13). The engineered
mutations are fairly conservative, causing relatively subtle
changes in amino acid side chains.
Recombination of mutant sequences into a wild-type HSV
background. To insert the mutant sequences generated in
bacteriophage M13 clones into a wild-type HSV back-
ground, the technique of marker rescue was used. To permit
propagation of viruses containing lethal pol mutations, the
DP6 cell line, which expresses HSV Pol and complements
otherwise nonviable HSV pol mutants, was used (40, 42).
HSV mutant HP66 (40, 42) was used to facilitate screening.
HP66 lacks 2.2 kb of pol sequences, which have been
replaced by a lacZ gene under the control of the HSV
thymidine kinase promoter. As a result, HP66 does not grow
on Vero cells but can grow on DP6 cells, on which it forms
blue plaques in the presence of 5-bromo-4-chloro-3-indolyl-
,-D-galactopyranoside (X-Gal) or Bluo-Gal.
HSV recombinants were then isolated by cotransfecting
HP66 infectious DNA with the various mutant bacteriophage
DNAs. Progeny from these transfections were plated onto
DP6 cells and stained with X-Gal or Bluo-Gal, and white
plaques were picked. Small viral stocks were grown from
each plaque pick and used to prepare viral DNA. This DNA
was then examined by Southern hybridization analysis (Fig.
2). EcoRI digests were analyzed to verify that recombination
took place at the proper site, and NciI digests were analyzed
to verify that the recombined segment lacked the NciI site in
the targeted area.
As can be seen in the example shown in Fig. 2, the EcoRI
fragment that hybridizes with an oligonucleotide derived
from the 3' end of the pol gene was 2.6 kbp in HP66 and was
4.1 kbp in the recombinants analyzed in lanes B and C and in
the wild-type HSV parental strain, KOS (the EcoRI M
fragment). Figure 2b shows that there is a shift in the size of
an Ncil fragment hybridizing with an oligonucleotide that
recognizes the fragment containing region IV, from 250 bp in
KOS to 325 bp in the recombinants in lanes B and C. HP66
lacks homologous sequences and thus did not hybridize with
the probe. Results of these and similar analyses showed that
the recombinant viruses E460D, V462A, and G464V all
a
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FIG. 2. Southem hybridization analysis of viral DNAs. Viral
DNA from plaque isolates or from KOS or HP66 was digested with
EcoRl (a) or Ncil (b), subjected to electrophoresis on a 0.7% (a) or
1.2% (b) agarose gel, transferred to GeneScreen II Plus overnight,
and hybridized to a 32P-labeled oligonucleotide specific for the
EcoRI fragment containing the 3' end of the pol gene (a) or region IV
(b). Lanes A to D represent DNA from four plaque isolates from a
marker rescue experiment with HP66 and pG464V.
contain mutant sequences at the proper location. These
viruses were plaque purified three times and used to prepare
high-titer stocks.
Mutants E460D and G464V are nonviable pol mutants. To
test whether particular mutations caused a lethal phenotype,
we examined the ability of the recombinant viruses derived
described above to grow on various cell lines. Recombinant
viruses E460D and G464V were viable on DP6 cells but not
on Vero or human 143 cells (plating efficiencies, <0.01%;
wild-type virus exhibits similar plating efficiencies on the
different cell lines). Because the only HSV gene present in
DP6 cells is pol (42), this result demonstrates that the lethal
phenotypes of these mutants are due to pol mutations.
To verify that the lethal phenotype of G464V was due to
the engineered mutation and not some other mutation, we
mapped and sequenced the mutation responsible. Infectious
G464V DNA was transfected by itself or with specific
wild-type DNA fragments from pDP1, and the progeny were
assayed for the ability to form plaques on Vero cells (Table
1). The fragments that rescued the ability of G464V to grow
TABLE 1. Marker rescue of G464V
Fragment Map location' Efficiencyb
No plasmid <0.0013
pDP1 1-1235 9.6
EcoRI-B 443-1235 0.57
EcoRI-A 1-440 <0.001
XhoI + HindIII-B 1-535 0.079
XhoI + HindIII-A+C 535-1235 <0.00001
"Expressed as amino acid residues in the HSV pOl open reading frame (24).
b Expressed as (titer on Vero cells/titer on DP6 cells) x 100. Values in
boldface are considered positive for rescue of growth on Vero cells.
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FIG. 3. Dot blot analysis of HSV DNA replication. Eight wells
each of Vero and DP6 cells, as indicated, were mock infected or
infected with wild-type KOS or recombinant G464V, E460D, or
V462A, as indicated. Total DNA was harvested at 0 or 20 h
postinfection, as indicated, blotted onto a nylon membrane, and
probed with a 32P-labeled oligonucleotide complementary to the
HSV pol gene.
on Vero cells overlap in a 277-bp fragment extending from an
EcoRI site on the upstream edge of region IV (amino acid
residue 443) to an XhoI site downstream of region IV
(residue 535). Preliminary marker rescue experiments with
mutant E460D also indicate that its lethal mutation maps
within the same 277 bp (24). The 4.1-kbp EcoRI M fragment
from G464V viral DNA was then isolated and cloned into
M13mpl9, and the relevant portion was sequenced. The
engineered mutation was the only alteration found within the
277-bp EcoRI-to-XhoI fragment, proving that this mutation
causes the lethal phenotype of G464V. Thus, the Exo II
segment of region IV contains residues that are critical for
HSV growth.
Mutant V462A is viable. In contrast to the other two
mutants, V462A was viable on both Vero and 143 cells
(plating efficiencies, ca. 100%). Moreover, the mutant plas-
mid, pV462A, was able to rescue the lethal phenotype of
HP66 efficiently (not shown). HSV mutant V462A also was
not detectably altered in its sensitivity to three diverse
antiviral drugs (21), in its frequency of spontaneous mutation
(21), or in its ability to kill mice following intracerebral
inoculation (48). The wild-type behavior of this Exo II
mutant provides a control for the phenotypes of the nonvi-
able mutants.
The nonviable Exo II mutants fail to synthesize viral DNA.
Since the sequences that we had mutagenized were within a
conserved 3'-5' exonuclease active site, we wished to deter-
mine whether mutants E460D and G464V failed to form
plaques because they accumulated too many replication
errors or because they failed to synthesize HSV DNA. Using
dot blot hybridization, we compared DNA synthesis from
the recombinants with that of wild-type virus in both Vero
and DP6 cells. As can be seen in Fig. 3, no accumulation of
HSV DNA was observed in Vero cells infected with either of
the lethal mutants E460D and G464V observed in the com-
plementing DP6 cells infected with these viruses. Recombi-
nant V462A exhibited wild-type levels of DNA in both cell
lines, as expected from its viable phenotype. Thus, the lethal
Exo II mutations abolish viral DNA synthesis.
TABLE 2. DNA polymerase activities in extracts of wild-type-
and mutant-infected cells
Infecting virus Activity (pmol/20 min)a % Activityb
None (mock infection) 50
KOS (wild type) 800 100
E460D 50 0
V462A 450 53
G464V 30 0
a Incorporation of radiolabeled TMP into DNA was measured. Each assay
contained 0.75 mg of total protein.
b Calculated as (mutant incorporation - mock incorporation)/(wild-type
incorporation - mock incorporation) x 100.
The nonviable Exo II mutants are defective for DNA poly-
merizing activity. Because the nonviable mutants failed to
synthesize viral DNA, we investigated whether they induced
active viral DNA polymerase activity. Human 143 cells were
mock infected or infected with wild-type strain KOS or with
each recombinant at a multiplicity of 10. Cell extracts were
prepared 8 h postinfection and assayed for polymerizing
activity on activated DNA primer-templates under condi-
tions optimal for HSV Pol (Table 2). Wild-type virus and the
viable recombinant V462A exhibited polymerase activities 9-
to 16-fold over mock-infected values; this variation was due
mainly to the difference in the amount of polymerase poly-
peptide present in the extracts (see below). In contrast, the
activities of the two nonviable mutants were severely im-
paired (<1% of wild-type values when mock-infected values
are subtracted). Similar results (70) were obtained with use
of EcoRI-digested DNA fragments as primer-templates, as
employed by Bernad et al. (2). In contrast, recombinants
derived by marker rescue of G464V and E460D exhibited
wild-type levels of polymerizing activity (70).
To ensure that the mutants expressed wild-type amounts
of HSV Pol polypeptide that remained stable during the
course of the assay, we performed Western blot analysis on
the extracts following polymerase assays. As can be seen in
Fig. 4A, extracts from cells infected with each mutant
contained a single major polypeptide that reacted with
specific anti-HSV Pol antisera (76). This species comigrated
with that in wild-type-infected cell extracts. Densitometric
scanning showed that the amounts of HSV Pol present in the
mutant extracts were .60% those found in wild-type ex-
w .v o-
.s,_..,.
__VW A Pol
IB ICP8
FIG. 4. Western blot analysis of mock-infected and virus-in-
fected cell extracts. Each lane contained approximately 50 ,ug of
total protein. Filters were probed successively with polyclonal sera
directed against HSV Pol (A) and ICP8 (B). The viruses used are
indicated above the lanes.
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FIG. 5. Coimmunoprecipitation of wild-type and mutant HSV Pol polypeptides with UL42. In vitro-transcribed mRNAs encoding the
various HSV Pol polypeptides were translated in rabbit reticulocyte lysate both with and without mRNA encoding UL42, as indicated, and
then analyzed by polyacrylamide gel electrophoresis either before (lanes 1) or after immunoprecipitation with an anti-HSV Pol (lanes 2) or
an anti-UL42 antiserum (lanes 3). Positions of the HSV Pol and UL42 polypeptides are indicated.
tracts. The results of Fig. 4B show that roughly equal
amounts of early viral proteins are present in each extract, as
assessed by Western blot analysis of the major viral DNA-
binding protein, ICP8. Densitometric scanning showed that
the amounts of HSV Pol polypeptide normalized to the
amount of ICP8 varied less than 25%. Thus, there was little
if any evidence for degradation of mutant polymerase. We
conclude that the defect in DNA polymerizing activity of the
mutants was not due to a lack of stable HSV Pol polypep-
tide.
Exo H mutant polymerase polypeptides associate with a
polymerase accessory protein. A possible reason why the Exo
II nonviable mutants could be defective in viral growth and
DNA polymerizing activity is that the mutations might
prevent proper folding of the polymerase in a global fashion.
As an initial test of this hypothesis, we assayed mutant
polymerase polypeptides for the ability to complex with the
HSV UL42 protein, which is an accessory subunit of HSV
Pol that increases processivity (26, 29). We used an assay for
complex formation that entails in vitro transcription and
translation of the pol and UL42 genes followed by immuno-
precipitation with antisera specific for each protein (14).
Whereas anti-polymerase antisera did not immunoprecipi-
tate UL42-size products when wild-type or mutant pol
mRNA or wild-type UL42 mRNA was translated alone, it
precipitated UL42 when the two mRNAs were translated
together (Fig. 5). Similarly, anti-UL42 antisera did not
immunoprecipitate polymerase-size products when any
mRNA was translated alone, but precipitated wild-type or
mutant polymerase polypeptides when pol and UL42 mR-
NAs were translated together (Fig. 5). In other experiments,
we detected HSV Pol-UL42 complexes in Exo II mutant-
infected Vero cells (not shown). Therefore, the Exo II
mutations did not prevent proper folding of HSV Pol to an
extent that it could not interact with UL42.
The nonviable Exo H mutant polymerases colocalize with
ICP8. As a second test for whether the Exo II mutations
affected other polymerase functions deleteriously, we inves-
tigated whether the mutant polymerases localized properly
in HSV-infected cells. In double-label immunofluorescence
experiments, Bush et al. (5) have shown that in the absence
of viral DNA synthesis, wild-type HSV Pol colocalizes in
infected cell nuclei with the major viral DNA-binding pro-
tein, ICP8, to nuclear structures called prereplicative sites.
These sites, which exhibit a characteristic punctate staining
pattern, appear to include viral and cellular components
required for DNA synthesis (5, 10, 50, 72). Proper localiza-
tion of HSV Pol to prereplicative sites requires ICP8; with
HSV ICP8 mutants or with transfected pol genes, HSV Pol
assumes a diffuse nuclear distribution (5). The nonviable
Exo II HSV mutants exhibited colocalization of polymerase
with ICP8 in prereplicative sites that was indistinguishable
from that of the wild type (Fig. 6). (Perinuclear staining with
the anti-polymerase antisera [Fig. 6B, D, and F] is due to
nonspecific binding of rabbit antibodies to some component
in the Golgi apparatus in infected cells.) We conclude that
the Exo II mutations permit proper entry of polymerase into
the nucleus and whatever interactions are required for it to
colocalize with ICP8 at prereplicative sites. We find no
evidence that these mutations lead to deleterious effects on
polymerase folding in a global fashion.
DISCUSSION
We have constructed three HSV recombinants containing
mutations in the Exo II segment of region IV of homology
shared among diverse DNA polymerases. Two of the recom-
binants, E460D and G464V, failed to grow in tissue culture
or to synthesize viral DNA in the absence of a complement-
ing pol gene. We have demonstrated by marker rescue and
DNA sequencing that the mutation G464V is lethal for viral
growth. This replication defect is associated with a profound
loss of DNA polymerizing activity and cannot be explained
by defects in polymerase synthesis, stability, ability to
associate with the accessory protein UL42, or ability to
properly colocalize with the DNA-binding protein ICP8.
These results have implications for the functions of this
region, especially given its homology with sites important for
3'-5' exonuclease function in E. coli Pol I and the a-like
DNA polymerases of bacteriophages T4 and 429.
Region IV is essential for viral growth and DNA replication.
Our results demonstrate that Exo II, and thus region IV, is
essential for viral growth, as might be predicted from the
degree of conservation of this region in a variety of DNA
polymerases. This finding is consistent with results for T4
and adenovirus, in which certain region IV mutations confer
temperature sensitivity or complete failure to grow (46, 51,
54-56, 73). It also demonstrates that region IV plays a
critical role in DNA synthesis per se. This finding is consis-
tent with observations for adenovirus and T4 temperature-
sensitive mutants that map within region IV or in the general
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FIG. 6. Double-label immunofluorescence staining of ICP8 and
HSV Pol in infected cells. CV-1 cells were infected with wild-type
HSV strain KOS (a and b), E460D (c and d), or G464V (e and f). At
5 h postinfection, the cells were fixed and reacted with anti-HSV Pol
antiserum PP5 and anti-ICP8 monoclonal antibody 39S, with biotin-
conjugated goat anti-rabbit immunoglobulin and rhodamine-conju-
gated goat anti-mouse immunoglobulin, and with fluorescein-conju-
gated avidin. (A) Cells infected with KOS. Image due to reaction
with anti-ICP8 antibody. (B) Same field of cells as in panel A; image
due to reaction with anti-HSV Pol antiserum. (C) Cells infected with
E460D. Image due to reaction with anti-ICP8 antibody. (D) Same
field of cells as in panel C; image due to reaction with anti-HSV Pol
antiserum. (E) Cells infected with G464V. Image due to reaction
with anti-ICP8 antibody. (F) Same field of cells as in panel E; image
due to reaction with anti-HSV Pol antiserum.
area, which have been shown to be DNA negative at the
nonpermissive temperature (17, 73, 74).
Region IV is essential for virus growth, but mapping of
drug resistance mutations (22, 23, 28, 35, 38, 40, 67) indicates
that it does not interact with polymerase dNTP or pyrophos-
phate analogs. Therefore, it might serve as a target for novel
antiviral drugs.
Do a-like DNA polymerases contain a distinct 3'-5' exonu-
clease domain? Comparisons among diverse DNA polymer-
ases identified three segments termed Exo I, II, and III with
homology to catalytically important segments of the 3'-5'
exonucleolytic activity of E. coli Pol I and related proteins
(2, 39, 45, 60). In the ax-like DNA polymerases encoded by
bacteriophages +29 and T4, mutations in or near Exo I, II,
and III, analogous to those in Pol I and T7, decrease 3'-5'
exonuclease activity, evidently without decreasing polymer-
ase activity (although the polymerase assays used would not
have detected effects on polymerase processivity) (2, 54).
These results have led to the hypothesis that, like Pol I,
a-like DNA polymerases contain a distinct 3'-5' exonuclease
domain that encompasses Exo I, II, and III (2, 53, 60).
Indeed, this hypothesis has formed the basis for several
efforts to predict structural features of a.-like DNA poly-
merases (11, 27, 52).
Our results argue against this simple picture. We intro-
duced two different and fairly conservative substitutions into
Exo II of the a-like DNA polymerase of HSV that resulted in
a drastic impairment of DNA synthesis in vivo and DNA
polymerizing activity in vitro. These results were not due to
lack of expression of the HSV Pol polypeptide or its stability
under polymerase assay conditions. We found no evidence
that the mutations caused global folding defects; the mutant
HSV Pol proteins were able to interact with the accessory
subunit, UL42, and to interact properly with cellular and
viral factors such that they localized correctly within in-
fected cell nuclei. The effects of the Exo II mutations on
polymerase activity contrast greatly with the results of
experiments in which a variety of point and even gross
deletion mutations were introduced into the 3'-5' exonucle-
ase domains of Pol I and T7 DNA polymerase, with little or
no effect on polymerizing activity (12, 13, 19, 61). Thus, in
HSV Pol, unlike Pol I or T7 DNA polymerase, polymeriza-
tion activity requires a sequence that is homologous to a
conserved 3'-5' exonuclease active site.
It could be argued that the G464V and E460D mutations
affect polymerase activity by trapping the DNA primer-
template in an otherwise inactive exonuclease active site.
Such an interpretation is complicated and would predict that
the mutations confer a dominant negative phenotype. The
data (e.g., Fig. 3) contradict the prediction. We therefore do
not favor such an interpretation.
We do not yet know whether the E460D and G464V Exo
II mutations affect 3'-5' exonuclease activity. This determi-
nation will likely require purification of the mutant enzymes,
since this activity is obscured in HSV-infected cells by other
nucleases. Therefore, we do not yet know whether Exo II or
any other Exo segment homology is important for the 3'-5'
exonuclease activity of HSV Pol, although, given the results
in the 429 and T4 systems (2, 54), we think it likely.
Regardless, our data indicate that these results in other
systems cannot be extrapolated to imply the existence of an
independent 3'-5' exonuclease domain in HSV Pol or at-like
polymerases in general. Indeed, we currently favor the
hypothesis that HSV Pol does not contain a 3'-5' exonucle-
ase domain with the functional and structural independence
of the Pol I domain.
Several other lines of evidence are consistent with our
favored hypothesis and suggest that it may apply to other
a-like DNA polymerases. Human and yeast DNA polymer-
ase a retain the Exo segment homologies (2), yet whether
they contain 3'-5' exonuclease activity remains controver-
sial. Mutations influencing sensitivity to drugs that mimic or
inhibit polymerases competitively with dNTP and pyrophos-
phate substrates have been mapped within or just upstream
of the Exo III segment in the a-like DNA polymerases
encoded by vaccinia virus (16, 66), HSV (28), M2 (45), and
+29 (44). Several other such mutations have been mapped
just downstream of Exo III in HSV (22, 28) (Fig. 1) and
vaccinia virus (62), and one of these clearly affects the Km
for dNTPs without effects on the ratio of exonuclease to
polymerase activity (13). Indeed, Exo III overlaps region A,
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which is proposed to join with regions I, II, III, and V in
forming the substrate binding sites of at-like DNA polymer-
ases (22). Nucleoside monophosphates, which inhibit the
3'-5' exonuclease activity of Pol I without affecting polymer-
ization (49), reportedly inhibit the polymerization activity of
HSV Pol (18). Numerous T4 and adenovirus mutations
within the putative 3'-5' exonuclease domain appear to affect
polymerizing activity (6, 52, 54, 55), although it is not clear
that these mutations do not exert global folding defects.
None of the results presented above has conclusively shown
that the polymerizing and exonuclease activities are insepa-
rable; nevertheless, they support our suggestion that many
a-like DNA polymerases do not contain polymerase and
exonuclease domains as distinct and independent as those of
Pol I and its relatives.
It is possible that 4(29 DNA polymerase exhibits greater
distinction between its polymerizing and exonuclease func-
tions than does HSV Pol. Consistent with this possibility is
the report that phosphonoacetic acid, which inhibits these
two activities of HSV Pol with equal potency (36), is a much
more potent inhibitor of 429 polymerizing activity than of its
3'-5' exonuclease (3). Moreover, equivalent Exo I mutations
have much less severe effects on the 3'-5' exonuclease of T4
DNA polymerase (54) than on that of429 (2). There may be
considerable variation in the interdependence of 3'-5' exo-
nuclease and polymerase functions among the different
a-like DNA polymerases.
Models for the domain structure of a-polymerases. We offer
two alternate models for those residues that have been
hypothesized to comprise a 3'-5' exonuclease domain of
ot-polymerases. The first is that this region does exist as a
distinct physical domain containing the 3'-5' exonuclease
activity, but, unlike the 3'-5' exonuclease domains of Pol I
and T7 DNA polymerase, it also performs important func-
tions during the polymerization process. This model may
entail movements of DNA, protein, or both during polymer-
ization. The second model is that a-polymerases contain
their polymerase and 3'-5' exonucleases on a single physical
domain and that the regions containing homology to 3'-5'
exonuclease active sites have been conserved to play roles
important for both activities. This could include holding
template DNA, as suggested by Matsumoto et al. (45).
Continued genetic, biochemical, and biophysical analyses
should permit resolution of competing models for a-poly-
merase structure and function.
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